Capricorn Fund Managers Ltd Takes $5.76 Million Position in MaxCyte, Inc. $MXCT

Capricorn Fund Managers Ltd acquired a new stake in MaxCyte, Inc. (NASDAQ:MXCT) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,200,000 shares of the company’s stock, valued at approximately $5,760,000. Capricorn Fund Managers Ltd owned 0.08% of MaxCyte at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MXCT. Prudential Financial Inc. purchased a new position in MaxCyte during the second quarter worth about $26,000. State of Wyoming purchased a new stake in shares of MaxCyte in the 2nd quarter valued at approximately $38,000. Jain Global LLC purchased a new stake in shares of MaxCyte in the 4th quarter valued at approximately $45,000. BNP Paribas Financial Markets increased its holdings in shares of MaxCyte by 266.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock worth $57,000 after buying an additional 18,913 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of MaxCyte during the 4th quarter worth approximately $67,000. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Stock Performance

Shares of MXCT stock opened at $1.23 on Wednesday. The firm has a market cap of $131.76 million, a P/E ratio of -3.32 and a beta of 1.48. The firm’s 50 day moving average price is $1.06 and its 200-day moving average price is $1.03. MaxCyte, Inc. has a one year low of $0.64 and a one year high of $2.37.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Tuesday, May 12th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.06. The firm had revenue of $6.22 million during the quarter, compared to the consensus estimate of $7.28 million. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. As a group, research analysts predict that MaxCyte, Inc. will post -0.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Craig Hallum reduced their price target on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. Weiss Ratings upgraded MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Finally, Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $5.50.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.